Personal and family history of immune-related conditions increase the risk of plasma cell disorders: A population-based study

Blood

Volumn 118, Issue 24, 2011, Pages 6284-6291

  Lindqvist, Ebba K ^a   Goldin, Lynn R ^b   Landgren, Ola ^a,b   Blimark, Cecilie ^c   Mellqvist, Ulf Henrik ^c   Turesson, Ingemar ^d   Wahlin, Anders ^e   Björkholm, Magnus ^a   Kristinsson, Sigurdur Y ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; M PROTEIN;

ADDISON DISEASE; ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANKYLOSING SPONDYLITIS; ANTIBODY DETECTION; APLASTIC ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; CELIAC DISEASE; CELLULITIS; CHLAMYDIA; CHRONIC ATROPHIC GASTRITIS; CHRONIC BRONCHITIS; CHRONIC GLOMERULONEPHRITIS; CHRONIC PROSTATITIS; CONTROLLED STUDY; CROHN DISEASE; CYSTITIS; CYTOMEGALOVIRUS INFECTION; DERMATITIS HERPETIFORMIS; DERMATOMYOSITIS; DISCOID LUPUS ERYTHEMATOSUS; DISEASE PREDISPOSITION; DIVERTICULITIS; DRESSLER SYNDROME; EMPYEMA; ENCEPHALITIS; ENDOCARDITIS; EPSTEIN BARR VIRUS; FAMILY HISTORY; FASCIITIS; FEMALE; GIANT CELL ARTERITIS; GINGIVITIS; GONORRHEA; GRAVES DISEASE; GUILLAIN BARRE SYNDROME; HASHIMOTO DISEASE; HELICOBACTER INFECTION; HEPATITIS A; HEPATITIS B; HEPATITIS C; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INFECTIOUS MONONUCLEOSIS; INFLAMMATION; INFLUENZA; INSULIN DEPENDENCE; INTESTINE INFECTION; LARYNGITIS; LYME DISEASE; MAJOR CLINICAL STUDY; MALARIA; MALE; MENINGITIS; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYOCARDITIS; NEPHRITIS; NEPHROTIC SYNDROME; OSTEOARTHRITIS; OSTEOMYELITIS; OTITIS MEDIA; PANCREATITIS; PEMPHIGUS; PERICARDITIS; PERIODONTITIS; PERNICIOUS ANEMIA; PNEUMONIA; POLYARTERITIS NODOSA; POLYMYOSITIS; POPULATION BASED CASE CONTROL STUDY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PSORIASIS; PYELONEPHRITIS; REITER SYNDROME; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; RHINITIS; RHINOPHARYNGITIS; RICKETTSIOSIS; RISK ASSESSMENT; SARCOIDOSIS; SEPTICEMIA; SINUSITIS; SJOEGREN SYNDROME; SYPHILIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TONSILLITIS; TUBERCULOSIS; ULCERATIVE COLITIS; VIRUS INFECTION;

EID: 83455259553     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-347559     Document Type: Article

References (34)

1. Swerdlov S, Campo E, Harris N, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th ed). Lyon, France: IARC; 2008.
2. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21-33. (Pubitemid 36033957)
3. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564-569. (Pubitemid 34438817)
4. Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113(22):5412-5417.
5. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009; 113(22):5418-5422.
6. Vachon CM, Kyle RA, Therneau TM, et al. Increased risk of monoclonal gammopathy in firstdegree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood. 2009;114(4): 785-790.
7. Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K, Goldin LR. Familial characteristics of autoimmune and hematologic disorders in 8406 multiple myeloma patients: a population-based case-control study. Int J Cancer. 2006; 118(12):3095-3098.
8. Landgren O, Kristinsson SY, Goldin LR, et al. Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood. 2009; 114(4):791-795.
9. Kristinsson SY, Bjorkholm M, Goldin LR, et al. Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. Int J Cancer. 2009;125(9):2147-2150.
10. Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia. 2009;23(10):1691-1697.
11. Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood. 2006;107(3):904- 906.
12. Landgren O, Kyle RA, Hoppin JA, et al. Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood. 2009;113(25):6386-6391.
13. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006; 354(13):1362-1369.
14. Alexander DD, Mink PJ, Adami HO, et al. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer. 2007;120(suppl 12):1-39. (Pubitemid 46732571)
15. Soderberg KC, Jonsson F, Winqvist O, Hagmar L, Feychting M. Autoimmune diseases, asthma and risk of haematological malignancies: a nationwide case-control study in Sweden. Eur J Cancer. 2006;42(17):3028-3033. (Pubitemid 44667472)
16. Anderson LA, Gadalla S, Morton LM, et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer. 2009;125(2):398-405.
17. Brown LM, Gridley G, Check D, Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood. 2008;111(7):3388-3394.
18. Landgren O, Rapkin JS, Mellemkjaer L, Gridley G, Goldin LR, Engels EA. Respiratory tract infections in the pathway to multiple myeloma: a population-based study in Scandinavia. Haematologica. 2006; 91(12):1697-1700. (Pubitemid 46032969)
19. Gregersen H, Pedersen G, Svendsen N, Thulstrup AM, Sorensen HT, Schonheyder HC. Multiple myeloma following an episode of community-acquired pneumococcal bacteraemia or meningitis. APMIS. 2001;109(11):797-800. (Pubitemid 34015462)
20. Swedish National Board of Health. Svenska cancerregistret. Stockholm, Sweden: Socialstyrelsen; 2008.
21. Turesson I, Linet MS, Bjorkholm M, et al. Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer. 2007;121(10):2260-2266. (Pubitemid 47585607)
22. Nilsson A, Spetz C, Carsjo K, Nightingale R, Smedby B. Slutenvårdsregistrets tillförlitlighet. Läkartidningen. 1994;91(7):598-605.
23. Swedish National Board of Health. Patientregistret. Stockholm, Sweden: Socialstyrelsen; 2008.
24. Skarle A. Flergenerationsregistret. Stockholm, Sweden: Statistics Sweden, Population Statistics; 2008.
25. Kristinsson SY, Koshiol J, Bjorkholm M, et al. Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. J Natl Cancer Inst. 2010;102(8):557-567.
26. Landgren O, Engels EA, Pfeiffer RM, et al. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst. 2006;98(18): 1321-1330. (Pubitemid 44530727)
27. Askling J, Klareskog L, Hjalgrim H, Baecklund E, Bjorkholm M, Ekbom A. Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis. Ann Rheum Dis. 2005;64(12):1765- 1768. (Pubitemid 41667153)
28. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH. Rheumatoid arthritis and cancer risk. Eur J Cancer. 1996;32A(10):1753-1757. (Pubitemid 26306889)
29. Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer. 2000;88(3):497-502.
30. Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis. 1978;31(11):691-696.
31. Neovius M, Sundstrom A, Simard J, et al. Smallarea variations in sales of TNF inhibitors in Sweden between 2000 and 2009. Scand J Rheumatol. 2011;40(1):8-15.
32. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64(4):1546-1558. (Pubitemid 38235629)
33. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106(1): 296-303. (Pubitemid 40967205)
34. MacLennan IC, Chapman C, Dunn J, Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis: the Medical Research Council Working Party for Leukaemia in Adults. Lancet. 1992;339(8787):200- 205.